Security
Cytosorbents Corporation Common Stock · CTSO
CTSONASDAQCommon stockCurrentCIK 1175151Updated Nov 13, 2026
Name history
MedaSorb Technologies CORP · through Apr 15, 2010GILDER ENTERPRISES INC · through Jul 24, 2006
CTSO price & chart
Loading TradingView…
NASDAQ:CTSO on TradingView ↗About the company
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, fo…
In the news
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference ↗
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026 ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 45,750,000Source | 47,804,011Source | 37,960,000Source | 47,990,000Source | 53,426,791Source | 40,562,000Source | 50,781,684Source | 47,070,605Source | 44,182,000Source | 47,371,500Source | 53,260,634Source | 63,231,530Source |
| Property, Plant and Equipment, NetUSD | 8,193,000Source | 9,269,899Source | 7,172,000Source | 8,466,000Source | 9,423,649Source | 7,510,000Source | 8,722,953Source | 9,748,651Source | 7,823,000Source | 9,002,383Source | 10,056,354Source | 10,743,032Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,536,000Source | 5,685,328Source | 4,413,000Source | 10,204,000Source | 8,458,708Source | 4,813,000Source | 11,587,275Source | 8,608,380Source | 6,249,000Source | 3,279,926Source | 14,131,137Source | 22,144,567Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 7,427,000Source | 6,632,590Source | 6,786,000Source | 7,743,000Source | 7,822,823Source | 7,152,000Source | 7,670,399Source | 6,765,290Source | 7,550,000Source | 7,319,597Source | 6,057,072Source | 5,664,941Source |
| Inventory, NetUSD | 4,002,000Source | 3,247,756Source | 3,686,000Source | 3,710,000Source | 4,316,752Source | 4,481,000Source | 3,018,524Source | 3,738,767Source | 5,281,000Source | 2,732,907Source | 3,680,129Source | 3,461,586Source |
| Assets, CurrentUSD | 21,313,000Source | 16,597,368Source | 15,737,000Source | 22,987,000Source | 21,955,300Source | 17,757,000Source | 25,412,904Source | 19,992,800Source | 20,634,000Source | 21,603,242Source | 25,702,823Source | 33,759,691Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,348,000Source | 1,031,694Source | 852,000Source | 1,330,000Source | 1,357,017Source | 1,311,000Source | 3,136,706Source | 880,363Source | 1,554,000Source | 3,270,812Source | 1,834,485Source | 2,488,597Source |
| Operating Lease, Right-of-Use AssetUSD | 11,075,000Source | 11,651,563Source | 10,612,000Source | 11,223,000Source | 11,789,539Source | 10,769,000Source | 11,368,340Source | 11,925,299Source | 10,924,000Source | 11,511,236Source | 12,058,896Source | 12,603,901Source |
| Other Assets, NoncurrentUSD | 3,647,000Source | 3,801,223Source | 53,000Source | 3,792,000Source | 3,774,345Source | 52,000Source | 3,755,029Source | 3,919,897Source | 53,000Source | 3,770,681Source | 3,958,603Source | 4,437,447Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 36,730,000Source | 34,804,921Source | 38,711,000Source | 36,404,000Source | 36,690,188Source | 38,368,000Source | 36,238,900Source | 28,142,680Source | 38,279,000Source | 36,264,564Source | 29,985,471Source | 27,856,557Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 63,000Source | 54,498Source | 63,000Source | 63,000Source | 54,306Source | 63,000Source | 62,529Source | 54,294Source | 63,000Source | 54,830Source | 54,240Source | 43,635Source |
| Additional Paid in CapitalUSD | 319,511,000Source | 308,441,887Source | 321,936,000Source | 319,023,000Source | 307,514,758Source | 321,568,000Source | 318,451,572Source | 305,984,268Source | 321,024,000Source | 310,808,711Source | 305,196,874Source | 287,000,021Source |
| Retained Earnings (Accumulated Deficit)USD | -306,710,000Source | -295,340,370Source | -321,754,000Source | -303,540,000Source | -293,006,279Source | -317,336,000Source | -305,486,976Source | -288,863,133Source | -312,207,000Source | -304,008,618Source | -282,505,272Source | -253,997,878Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -3,844,000Source | -156,925Source | -996,000Source | -3,960,000Source | 2,173,818Source | -2,101,000Source | 1,515,659Source | 1,752,496Source | -2,977,000Source | 4,252,013Source | 529,321Source | 2,329,195Source |
| Stockholders' Equity Attributable to ParentUSD | 9,020,000Source | 13,383,000Source | -751,000Source | 11,586,000Source | 17,427,000Source | 2,194,000Source | 14,541,000Source | 19,628,382Source | 5,903,000Source | 11,106,936Source | 23,275,163Source | 35,374,973Source |
| Liabilities and EquityUSD | 45,750,000Source | 47,804,011Source | 37,960,000Source | 47,990,000Source | 53,426,791Source | 40,562,000Source | 50,781,684Source | 47,070,605Source | 44,182,000Source | 47,371,500Source | 53,260,634Source | 63,231,530Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,112,000Source | 8,430,191Source | 24,023,000Source | 9,842,000Source | 10,336,268Source | 16,303,000Source | 9,736,066Source | 13,424,101Source | 9,709,000Source | 9,824,243Source | 14,545,955Source | 9,714,552Source |
| Operating Lease, Liability, CurrentUSD | 518,000Source | 431,997Source | 589,000Source | 495,000Source | 412,067Source | 565,000Source | 473,889Source | 392,617Source | 541,000Source | 452,688Source | 373,636Source | 108,939Source |
| Accounts Payable, CurrentUSD | 3,035,000Source | 2,338,143Source | 2,002,000Source | 3,394,000Source | 3,047,038Source | 3,132,000Source | 3,325,386Source | 2,399,421Source | 2,869,000Source | 3,339,885Source | 3,802,170Source | 1,655,173Source |
| Operating Lease, Liability, NoncurrentUSD | 12,051,000Source | 12,568,745Source | 11,596,000Source | 12,185,000Source | 12,680,725Source | 11,752,000Source | 12,316,119Source | 12,790,008Source | 11,903,000Source | 12,443,971Source | 12,896,659Source | 13,142,005Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 497,627Source | 850,630Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 14,149,000Source | — | — | 6,646,000Source | — | 2,500,000Source | — | — | 2,500,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 14,567,000Source | 13,805,985Source | 3,092,000Source | 14,377,000Source | 13,673,195Source | 10,313,000Source | 14,186,715Source | 1,928,571Source | 16,667,000Source | 13,996,350Source | 2,542,857Source | 5,000,000Source |
| Deferred Revenue, Current | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -5,129,000Source | -1,479,000Source | -8,198,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 488,000Source | 891,000Source | 368,000Source | 571,000Source | 544,000Source | 818,000Source | 2,765,000Source | 3,759,534Source | 3,329,307Source | 3,423,517Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -310,000Source | 80,000Source | -423,000Source | 1,720,419Source | 245,616Source | 1,288,422Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -723,000Source | 199,000Source | 2,540,000Source | -500,466Source | 121,039Source | -945,352Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,162,000Source | -3,466,000Source | -12,377,000Source | -14,427,809Source | -21,655,136Source | -28,234,282Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -46,000Source | -47,000Source | -415,000Source | -669,430Source | -936,236Source | -6,455,576Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 11,000Source | 2,000Source | 164,000Source | 284,343Source | 538,115Source | 6,087,365Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 6,831,000Source | 9,309,000Source | 9,330,704Source | 14,474,210Source | 4,959,642Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 5,000,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,436,000Source | 3,346,000Source | -1,993,000Source | -5,851,211Source | -8,216,931Source | -29,993,140Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 9,058,000Source | 12,168,000Source | 5,935,000Source | 11,726,000Source | 6,335,000Source | 13,110,000Source | 7,771,000Source | 9,763,884Source | 15,615,095Source | 23,832,026Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 591,000Source | 506,000Source | 2,082,000Source | 1,290,396Source | 376,668Source | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | -1,712,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | 100,000Source | 100,000Source | — | — | — | 62,800Source | 300,000Source | 235,146Source | 222,836Source | 194,056Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 782,000Source | — | — | 418,000Source | 627,000Source | 2,800,000Source | 3,800,000Source | 3,329,000Source | 3,424,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | 60,000Source | 60,000Source | 61,000Source | 63,000Source | 262,000Source | — | — | — |
| DepreciationUSD | — | — | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 289,000Source | 306,000Source | 1,200,000Source | 1,341,262Source | 1,239,600Source | 688,565Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -64,000Source | 2,650,000Source | -911,000Source | 6,178,000Source | -1,228,000Source | 3,014,000Source | 9,321,000Source | -4,224,721Source | 1,949,257Source | -2,448,583Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -1,228,000Source | 3,014,000Source | 9,321,000Source | -4,224,721Source | 1,949,256Source | -2,448,583Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | -132,303Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 280,000Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | 274,000Source | 8,000Source | — | 333,735Source | 655,685Source | 635,606Source |
| Income Tax Expense (Benefit)USD | — | — | -401,000Source | 0Source | 0Source | 0Source | 0Source | 0Source | -401,000Source | -1,690,825Source | -813,739Source | -1,092,585Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 253,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,170,000Source | -2,768,000Source | -4,417,000Source | 1,947,000Source | -5,129,000Source | -1,479,000Source | -8,198,000Source | -20,718,957Source | -28,507,394Source | -32,812,583Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,170,000Source | -2,768,000Source | -4,417,000Source | 1,947,000Source | -5,129,000Source | -1,479,000Source | -8,198,000Source | -20,718,957Source | -28,507,394Source | -32,812,583Source |
| Nonoperating Income (Expense)USD | — | — | -709,000Source | 2,062,000Source | -1,779,000Source | 5,562,000Source | -2,085,000Source | 2,409,000Source | 6,150,000Source | -5,623,843Source | 1,888,120Source | -2,383,289Source |
| Operating ExpensesUSD | — | — | 9,528,000Source | 10,086,000Source | 9,687,000Source | 10,429,000Source | 9,174,000Source | 10,095,000Source | 41,240,000Source | 41,911,930Source | 53,601,276Source | 52,254,936Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | 461,541Source | — | 2,234,616Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 2,478,000Source | 15,000,000Source | — | 5,000,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 218,278Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 9,485,000Source | 8,613,000Source | — | 9,617,000Source | 8,864,000Source | 8,727,000Source | 37,063,000Source | 35,594,520Source | 36,349,379Source | 34,688,809Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 260,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of RevenueUSD | — | — | 2,819,000Source | 3,357,000Source | 2,584,000Source | 2,803,000Source | 2,734,000Source | 2,520,000Source | 10,572,000Source | 10,468,529Source | 13,957,356Source | 13,955,752Source |
| Selling, General and Administrative ExpenseUSD | — | — | 8,610,000Source | 8,260,000Source | 7,964,000Source | 9,167,000Source | 8,149,000Source | 8,432,000Source | 35,645,000Source | 34,995,749Source | 33,600,065Source | 34,288,130Source |
| Operating Income (Loss)USD | — | — | -2,862,000Source | -4,830,000Source | -2,638,000Source | -3,615,000Source | -3,044,000Source | -3,888,000Source | -14,749,000Source | -16,785,939Source | -31,209,253Source | -31,521,879Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -3,571,000Source | -2,768,000Source | — | — | — | -1,478,358Source | -8,599,000Source | -22,409,782Source | -29,321,133Source | -33,905,168Source |
| Income Tax Expense (Benefit)USD | — | — | -401,000Source | 0Source | 0Source | 0Source | 0Source | 0Source | -401,000Source | -1,690,825Source | -813,739Source | -1,092,585Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,170,000Source | -2,768,000Source | -4,417,000Source | 1,947,000Source | -5,129,000Source | -1,479,000Source | -8,198,000Source | -20,718,957Source | -28,507,394Source | -32,812,583Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.05Source | -0.05Source | -0.07Source | 0.03Source | -0.08Source | -0.02Source | -0.13Source | -0.38Source | -0.64Source | -0.75Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.05Source | -0.05Source | -0.07Source | 0.03Source | -0.08Source | -0.02Source | -0.13Source | -0.38Source | -0.64Source | -0.75Source |
| Total Revenue | — | — | — | — | — | — | — | — | — | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 62,753,959Source | 54,453,006Source | 62,806,694Source | 62,608,598Source | 62,738,827Source | 60,731,929Source | 62,231,771Source | 54,434,609Source | 44,656,391Source | 43,573,215Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 62,753,959Source | 54,453,006Source | 62,806,694Source | 67,166,377Source | 62,738,827Source | 60,731,929Source | 62,231,771Source | 54,434,609Source | 44,656,391Source | 43,573,215Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | 60,000Source | 60,000Source | 61,000Source | 63,000Source | 262,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -401,000Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | 368,503Source | 1,234,000Source | 1,570,104Source | 1,462,436Source | 882,621Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -64,000Source | 2,650,000Source | -911,000Source | 6,178,000Source | -1,228,000Source | 3,014,000Source | 9,321,000Source | -4,224,721Source | 1,949,257Source | -2,448,583Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 280,000Source | — |
| Gross ProfitUSD | — | — | 6,666,000Source | 5,256,000Source | 7,049,000Source | 6,814,000Source | 6,130,000Source | 6,207,000Source | 26,491,000Source | 25,125,991Source | 22,392,023Source | 20,733,057Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -9,608,000Source | -11,722,734Source | -21,475,931Source | -21,155,203Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -645,000Source | -588,000Source | -868,000Source | -616,000Source | -857,000Source | -605,000Source | -2,612,000Source | -1,399,092Source | -157,891Source | 132,597Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,170,000Source | -2,768,000Source | -4,417,000Source | 1,947,000Source | -5,129,000Source | -1,479,000Source | -8,198,000Source | -20,718,957Source | -28,507,394Source | -32,812,583Source |
| Nonoperating Income (Expense)USD | — | — | -709,000Source | 2,062,000Source | -1,779,000Source | 5,562,000Source | -2,085,000Source | 2,409,000Source | 6,150,000Source | -5,623,843Source | 1,888,120Source | -2,383,289Source |
| Operating ExpensesUSD | — | — | 9,528,000Source | 10,086,000Source | 9,687,000Source | 10,429,000Source | 9,174,000Source | 10,095,000Source | 41,240,000Source | 41,911,930Source | 53,601,276Source | 52,254,936Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | 461,541Source | — | 2,234,616Source | — | — |
| Research and Development ExpenseUSD | — | — | — | 1,851,230Source | 1,453,000Source | 1,262,000Source | 1,025,000Source | 1,663,000Source | — | — | 15,728,915Source | 15,118,907Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 9,485,000Source | 8,613,000Source | — | 9,617,000Source | 8,864,000Source | 8,727,000Source | 37,063,000Source | 35,594,520Source | 36,349,379Source | 34,688,809Source |
| Total Revenue | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Other General and Administrative Expense | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
Filing attachments
tm2625982d1_ex99-1.htm · 8-K · 2026-09-23
Exhibit 99.1 CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J., September 23, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with the Nasdaq Stock Market’s minimum bid price requirement of $1.00 per share. On September 22, 2026, CytoSorbents received notification from the Listing Qu…
Read attachment ↗tm2622604d1_ex99-1.htm · 8-K · 2026-08-07
EX-99.1 2 tm2622604d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Corporation Nasdaq: CTSO Q2 2026 Earnings Conference Call August 6, 2026 Statements in this presentation include forward - looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward - looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, re…
Read attachment ↗tm2622246d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622246d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ende…
Read attachment ↗tm2618977d1_ex99-1.htm · 8-K · 2026-06-25
EX-99.1 2 tm2618977d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 | 1 1 NASDAQ: CTSO Life Sciences Forum June 24, 2026 | 2 2 Safe Harbor Statement Statements in this presentation include forward - looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward - looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, represe…
Read attachment ↗tm2523975d1_ex99-1.htm · 8-K · 2025-08-20
EX-99.1 2 tm2523975d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization PRINCETON, N.J., August 20, 2025 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, up…
Read attachment ↗tm2522255d1_ex99-1.htm · 8-K · 2025-08-01
EX-99.1 2 tm2522255d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Leads a New Era in Sepsis Treatment CytoSorbents highlights the vital and evolving role of CytoSorb® in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10th PRINCETON, N.J., July 31, 2025 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, highlight…
Read attachment ↗